The tail-end enrichment of cell cycle and a higher proportion of Ki67 low-expressing patients, implied a reduced capacity for tumor growth and proliferation in subtype 1, resulting in smaller tumor size and favorable prognosis. Here, MKI67 is linked to neoplasm.